TPST · Tempest Therapeutics, Inc.

The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.

This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.

The shares are held by Factor Bioscience Inc. ("Factor"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.

On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.

The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.

On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.

The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.

The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval.

The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.

On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.

The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.

The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.

The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.

This option shall vest with respect to 25% of the total number of shares underlying the option on February 4, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.

The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.35 to $1.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

Includes 11,376 shares acquired under the Issuer's stock purchase plan.

Includes 3,000 shares acquired under the Issuer's stock purchase plan.

Includes 14,668 shares acquired under the Issuer's stock purchase plan.

The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service.

25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.

25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.

25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.

25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.

The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

The shares underlying the option will vest in 48 equal monthly installments commencing on November 3, 2022, subject to the Reporting Person's continuous service through each vesting date.

Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.